PURPOSE: There is currently no standard chemotherapy regimen for patients with lymphoid malignancies being considered for reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation (RIC-alloHSCT). The ideal regimen would provide disease control and result in lymphocyte depletion to facilitate engraftment. To this end, we developed a novel regimen by adding fludarabine to dose-adjusted continuous-infusion etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin plus with or without rituximab (DA-EPOCH-F/R). PATIENTS AND METHODS: One hundred forty-seven patients with lymphoid malignancy (median age, 50 years) who had heavily pretreated (median prior regimens, three) and chemo-refractory (47%) disease were treated with DA-EPOCH-F/R before RIC-alloHSCT. Patients received one to three consecutive cycles until achieving lymphocyte depletion (CD4(+) count < 200/μL) or progressive disease. RESULTS: Overall response rate was 41%; 39% of patients had stable disease. Toxicity included grade 4 neutropenia in 65% and thrombocytopenia in 25% of patients. DA-EPOCH-F/R resulted in lymphocyte depletion (P < .001), which was inversely associated with serum interleukin (IL) 7 and IL-15 levels. Of 147 patients, 143 patients proceeded to RIC-alloHSCT. Patients with lower CD3(+) (P < .001), CD4(+) (P < .001), and CD8(+) (P < .001) T-cell counts after DA-EPOCH-F/R were more likely to achieve full donor lymphoid chimerism by day +14 after transplant. Relative to nonresponders to DA-EPOCH-F/R, patients with complete and partial response had increased event-free survival (77.4 v 4.8 months; P < .001) and overall survival (98.5 v 16.2 months; P < .001). CONCLUSION: DA-EPOCH-F/R safely provides tumor cytoreduction and lymphocyte depletion, thereby offering a bridge to RIC-alloHSCT in patients with aggressive lymphoid malignancies.
PURPOSE: There is currently no standard chemotherapy regimen for patients with lymphoid malignancies being considered for reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation (RIC-alloHSCT). The ideal regimen would provide disease control and result in lymphocyte depletion to facilitate engraftment. To this end, we developed a novel regimen by adding fludarabine to dose-adjusted continuous-infusion etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin plus with or without rituximab (DA-EPOCH-F/R). PATIENTS AND METHODS: One hundred forty-seven patients with lymphoid malignancy (median age, 50 years) who had heavily pretreated (median prior regimens, three) and chemo-refractory (47%) disease were treated with DA-EPOCH-F/R before RIC-alloHSCT. Patients received one to three consecutive cycles until achieving lymphocyte depletion (CD4(+) count < 200/μL) or progressive disease. RESULTS: Overall response rate was 41%; 39% of patients had stable disease. Toxicity included grade 4 neutropenia in 65% and thrombocytopenia in 25% of patients. DA-EPOCH-F/R resulted in lymphocyte depletion (P < .001), which was inversely associated with serum interleukin (IL) 7 and IL-15 levels. Of 147 patients, 143 patients proceeded to RIC-alloHSCT. Patients with lower CD3(+) (P < .001), CD4(+) (P < .001), and CD8(+) (P < .001) T-cell counts after DA-EPOCH-F/R were more likely to achieve full donor lymphoid chimerism by day +14 after transplant. Relative to nonresponders to DA-EPOCH-F/R, patients with complete and partial response had increased event-free survival (77.4 v 4.8 months; P < .001) and overall survival (98.5 v 16.2 months; P < .001). CONCLUSION:DA-EPOCH-F/R safely provides tumor cytoreduction and lymphocyte depletion, thereby offering a bridge to RIC-alloHSCT in patients with aggressive lymphoid malignancies.
Authors: I F Khouri; R M Saliba; S A Giralt; M S Lee; G J Okoroji; F B Hagemeister; M Korbling; A Younes; C Ippoliti; J L Gajewski; P McLaughlin; P Anderlini; M L Donato; F F Cabanillas; R E Champlin Journal: Blood Date: 2001-12-15 Impact factor: 22.113
Authors: Wyndham H Wilson; Michael L Grossbard; Stefania Pittaluga; Diane Cole; Deborah Pearson; Nicole Drbohlav; Seth M Steinberg; Richard F Little; John Janik; Martin Gutierrez; Mark Raffeld; Louis Staudt; Bruce D Cheson; Dan L Longo; Nancy Harris; Elaine S Jaffe; Bruce A Chabner; Robert Wittes; Frank Balis Journal: Blood Date: 2002-04-15 Impact factor: 22.113
Authors: J A Pérez-Simón; D Caballero; M Diez-Campelo; R Lopez-Pérez; G Mateos; C Cañizo; L Vazquez; B Vidriales; M V Mateos; M Gonzalez; J F San Miguel Journal: Leukemia Date: 2002-08 Impact factor: 11.528
Authors: D Valcárcel; R Martino; D Caballero; M V Mateos; J A Pérez-Simón; C Canals; F Fernández; J Bargay; E Muñiz-Díaz; M Gonzalez; J F San Miguel; J Sierra Journal: Bone Marrow Transplant Date: 2003-03 Impact factor: 5.483
Authors: Stephen P Robinson; Anthony H Goldstone; Stephen Mackinnon; Angelo Carella; Nigel Russell; Carmen Ruiz de Elvira; Goli Taghipour; Norbert Schmitz Journal: Blood Date: 2002-08-15 Impact factor: 22.113
Authors: Issa F Khouri; Ming-S Lee; Rima M Saliba; Gu Jun; Luis Fayad; Anas Younes; Barbara Pro; Sandra Acholonu; Peter McLaughlin; Ruth L Katz; Richard E Champlin Journal: J Clin Oncol Date: 2003-12-01 Impact factor: 44.544
Authors: Sencer Goklemez; Sarfaraz Hasni; Frances T Hakim; Paolo A Muraro; Filip Pirsl; Jeremy Rose; Sarfraz Memon; Daniel F Fowler; Seth M Steinberg; Eva H Baker; Sandya R Panch; Ronald Gress; Gabor G Illei; Peter E Lipsky; Steven Z Pavletic Journal: Rheumatology (Oxford) Date: 2022-08-03 Impact factor: 7.046
Authors: Daniel H Fowler; Miriam E Mossoba; Seth M Steinberg; David C Halverson; David Stroncek; Hahn M Khuu; Frances T Hakim; Luciano Castiello; Marianna Sabatino; Susan F Leitman; Jacopo Mariotti; Juan C Gea-Banacloche; Claude Sportes; Nancy M Hardy; Dennis D Hickstein; Steven Z Pavletic; Scott Rowley; Andre Goy; Michele Donato; Robert Korngold; Andrew Pecora; Bruce L Levine; Carl H June; Ronald E Gress; Michael R Bishop Journal: Blood Date: 2013-02-20 Impact factor: 22.113
Authors: Brian C Shaffer; Marko Modric; Maryalice Stetler-Stevenson; Diane C Arthur; Seth M Steinberg; David J Liewehr; Daniel H Fowler; Robert P Gale; Michael R Bishop; Steven Z Pavletic Journal: Exp Hematol Date: 2013-05-18 Impact factor: 3.084
Authors: Ran Reshef; Elizabeth O Hexner; Alison W Loren; Noelle V Frey; Edward A Stadtmauer; Selina M Luger; James K Mangan; Saar I Gill; Pavel Vassilev; Kathryn A Lafferty; Jacqueline Smith; Vivianna M Van Deerlin; Rosemarie Mick; David L Porter Journal: Biol Blood Marrow Transplant Date: 2014-07-10 Impact factor: 5.742
Authors: Rachel B Salit; Daniel H Fowler; Robert M Dean; Steven Z Pavletic; Frances T Hakim; Seth M Steinberg; Nancy T Hardy; Claude Sportes; Ronald E Gress; Michael R Bishop Journal: Biol Blood Marrow Transplant Date: 2013-08-13 Impact factor: 5.742
Authors: Linda M Griffith; Mark VanRaden; A John Barrett; Richard W Childs; Daniel H Fowler; Elizabeth M Kang; John F Tisdale; Harvey G Klein; David F Stroncek Journal: Transfusion Date: 2018-10-26 Impact factor: 3.157